Key result
Multimodal imaging enhances diagnostic accuracy and guides treatment for AL and ATTR cardiac amyloidosis.
Why the study?
Cardiac amyloidosis is an underdiagnosed cause of heart failure, and advances in non-invasive imaging have enhanced diagnostic accuracy and monitoring.
Multimodality imaging, including echocardiography, CMR, and radionuclide imaging, plays a critical role in guiding the diagnosis, prognosis, and therapeutic decisions for patients with cardiac amyloidosis.
Supports multimodal imaging integration in cardiac amyloidosis; leaves open prospective trials to confirm outcome impact.
Cardiac amyloidosis is an underdiagnosed cause of heart failure characterized by extracellular deposition of misfolded proteins. Advances in non-invasive imaging, including echocardiography, cardiac magnetic resonance imaging (CMR), and radionuclide imaging, have significantly enhanced the diagnostic accuracy and monitoring of cardiac amyloidosis. This review explores the role of each modality, their individual strengths, and current consensus recommendations. Emphasis is placed on the integration of multimodal imaging to guide diagnosis, prognosis, and therapeutic decisions in both AL and ATTR amyloidosis.
No takes yet. Share an insight, caveat, or question.
Chaudhari et al. (2025) studied this question. Multimodal imaging significantly enhances the diagnostic accuracy and monitoring of cardiac amyloidosis, guiding diagnosis and treatment decisions for AL and ATTR types.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: